Institutional Repository UDD

Resultados anatómicos y refractivos en pacientes tratados por retinopatía del prematuro

Show simple item record

dc.contributor.author Lolas, M
dc.contributor.author Tuma, Anton
dc.contributor.author Zanolli, Mario
dc.contributor.author Agurto, Ricardo
dc.contributor.author Stevenson, Ricardo
dc.contributor.author Ossandón, Diego
dc.date.accessioned 2017-08-28T19:07:15Z
dc.date.available 2017-08-28T19:07:15Z
dc.date.issued 2017
dc.identifier.citation Arch Soc Esp Oftalmol. 2017 Jun 14. pii: S0365-6691(17)30009-6 es_CL
dc.identifier.uri https://doi.org/10.1016/j.oftal.2016.12.007 es_CL
dc.identifier.uri http://hdl.handle.net/11447/1609
dc.description.abstract OBJECTIVE: To describe the anatomical and refractive outcomes after treatment with intravitreal bevacizumab or laser in a patient cohort with retinopathy of prematurity (ROP). METHODS: A multicentre, prospective, and observational study was performed on patients with ROP treated at Hospital Roberto del Río. Those patients with less than 6months of follow-up were excluded. Cases with posterior zone II, zone I ROP, and aggressive posterior ROP (AP-ROP) were treated with intravitreal bevacizumab. All other patients were treated with laser. Follow-up was performed every 3 months, and included fondo evaluation, refraction, and Teller tests. RESULTS: The treated group included 144 eyes of 72 patients, of whom 49 were treated with laser and 23 with intravitreal bevacizumab. One (1.4%) patient from the laser group progressed to stage 4b retinal detachment and required bilateral vitrectomy. Of the remainder, 45 cases had type 1 ROP, 16 had threshold disease, and 11 had AP-ROP. The median of gestational age was 26 weeks (range 23-30), and median of birth weight was 800g (range 405-1350). Median follow-up was 10 months (range 6-8). The Teller test median was 3.2 cycles/cm (range 0.32-13). There were 16 (22%) cases with a myopic refraction of -6 D or more. The sphere median was -1.75 D (range -16.00 to +3.50 D) and the cylindrical median was 0.00 (range -4.5 to +1.5 D). Anatomical success was achieved in 71 (98.6%) of patients. CONCLUSION: Treatment with laser or intravitreal bevacizumab is a highly successful primary treatment for ROP. Anatomical success can be achieved in most cases. Treated patients develop frequent and severe refractive defects, which should be corrected. Vision outcome, measured using the Teller preferential test, shows good results es_CL
dc.format.extent 1 es_CL
dc.language.iso spa es_CL
dc.publisher Elsevier es_CL
dc.subject Bevacizumab es_CL
dc.subject Laser es_CL
dc.subject Retinopathy of prematurity es_CL
dc.title Resultados anatómicos y refractivos en pacientes tratados por retinopatía del prematuro es_CL
dc.title.alternative Anatomical and refractive outcomes in patients with treated retinopathy of prematurity es_CL
dc.type Artículo es_CL


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account